This study looks at the safety and effectiveness of NalIriFOx, a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). Metastatic means the cancer has spread to other parts of the body. Pancreatic cancer is often found late, making it hard to treat. NalIriFOx is a mix of drugs that may work better and be easier on the body than other treatments.
- This study is open-label and non-interventional, meaning doctors and patients will know the treatment given, and no extra tests or procedures will be done.
- Participants need to have mPDAC and receive NalIriFOx as their first treatment for this cancer.
- Patients will not receive payment, but their participation could help improve treatment strategies for others in the future.
People can join if they have confirmed mPDAC and agree to participate. They cannot join if they had certain treatments before or if they don’t fit the study criteria. This research aims to gather real-world data, which helps understand how well treatments work in everyday settings outside of controlled trials.
How understandable was the trial content above?
Hard to understand
Easy to understand